Tag: healthcare

What’s Next in Healthcare Mergers & Acquisitions

Capstone CEO and Founder David Braun is the author of an article for Managed Healthcare Executive magazine. The article examines recent merger activity within the healthcare industry and looks at potential future trends in healthcare M&A. Read the entire article at: https://www.managedhealthcareexecutive.com/view/what-s-next-in-healthcare-mergers-acquisitions

M&A Growth Strategy for Healthcare Companies

Regarding mergers and acquisitions, the healthcare industry was one of the most active in 2021. Capstone Strategic Founder and CEO David Braun recently spoke with the publication Healthcare Business Today to share some insight on growth strategy for healthcare companies considering M&A. https://www.healthcarebusinesstoday.com/ma-growth-strategy-for-healthcare-companies/  

Capstone Strategic Advises Immanuel in Acquisition of Senior Living Community The Shores at Pleasant Hill

Capstone Strategic announced today that Immanuel, a leader in the field of retirement living in the Midwest has acquired senior living community The Shores at Pleasant Hill. With this acquisition, Immanuel gains its first senior living community in Iowa and builds on its mission of serving seniors in the region. Capstone Strategic, Inc. (Capstone) announced today …

Continue reading

Capstone Strategic Guides Immanuel on “Not-for-Sale” Acquisition of Senior Living Community Clark Jeary

Capstone Strategic announced today that Immanuel, a leader in the field of retirement living in Nebraska has acquired senior living community Clark Jeary. The deal expands Immanuel’s geographic footprint in Lincoln and adds to its mission of serving seniors. Capstone Strategic, Inc. (Capstone) announced today that Immanuel has acquired Clark Jeary, a 122-apartment senior living community …

Continue reading

Growing Demand in Healthcare Sectors Drives M&A

Thanks to advances in science and healthcare, people are living longer than ever. As they age, demand for healthcare products and services increases. One of the most significant demographic trends impacting healthcare is the aging baby boomer generation. As about 75 million American baby boomers grow older, demand for healthcare continue to will increase rapidly. …

Continue reading

Pfizer and Allergan Break Up: Lessons in Staying Ahead of M&A Hazards

Pfizer and Allergan have announced that they are abandoning their $160 billion merger. This resulted from a political storm around tax inversions, a technique whereby US companies relocate abroad to avoid the high US corporate tax rates. The Treasury department took action to insert new rules that effectively killed the financial benefits of the deal. …

Continue reading

What will happen in M&A in Q1 2016? Dealmakers Weigh In

As we near the end of the fourth quarter, everyone is wondering what will happen in 2016. Will the frenzied M&A activity of 2015 continue into the new year? There seem to be mixed reviews on what activity will look like next year. The Intralinks deal flow predictor indicates a 7% increase in global M&A …

Continue reading

The Middle Market Guide to Navigating Through the Wave of Healthcare M&A

The pharmaceutical and healthcare industry shows no sign of slowing down in terms of M&A and consolidation. There have already been $427 billion in transactions according to Dealogic data. Last week Pfizer and Allergan announced that they are currently in merger talks to form one of the largest pharmaceutical companies in the world. Certainly one …

Continue reading

Pharmaceutical M&A: The Rush to Acquire

Last week alone, there were three major consolidations in the pharmaceutical space: Teva will acquire the generic business of Allergan Hikma pharmaceuticals will acquire Roxane, Boehringer Ingelheim’s generic drug business Mylan will acquire Perrigo These three deals in just a few days reflect the trend of pharmaceutical consolidation as companies seek new products in order to …

Continue reading

Endo Grows Generic Drug Business with Par Pharma Acquisition

On May 18, Endo announced it would acquire Par Pharmaceutical for $6.5 billion cash and $1.5 billion stock. The acquisition is the latest consolidation in a robust M&A market, especially in the healthcare sector. Endo has stated multiple reasons for the deal, including building its generic drug platform as well as significant operational and tax …

Continue reading

Load more